Allogene Therapeutics, Inc. (ALLO) has a consensus analyst rating of Buy, based on 29 analysts covering the stock. Of those, 19 recommend buying, 8 recommend holding, and 2 recommend selling.
The analyst consensus price target for ALLO is $29.00, representing a +1,171.9% upside from the current price of $2.28. Price targets range from a low of $7.00 to a high of $55.00.
